Question 1

Am I eligible for this trial based on my current health and cancer status?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the First-line Treatment With Dacomitinib Plus Anlotinib for Patients With Advanced NSCLC With EGFR 21L858R Mutations clinical trial (NCT05271916). Contact the study team or your healthcare provider for specific answers.

Question 2

What are the potential side effects of dacomitinib and anlotinib?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the First-line Treatment With Dacomitinib Plus Anlotinib for Patients With Advanced NSCLC With EGFR 21L858R Mutations clinical trial (NCT05271916). Contact the study team or your healthcare provider for specific answers.

Question 3

How does this treatment compare to other options available for my condition?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the First-line Treatment With Dacomitinib Plus Anlotinib for Patients With Advanced NSCLC With EGFR 21L858R Mutations clinical trial (NCT05271916). Contact the study team or your healthcare provider for specific answers.

Question 4

What will my treatment schedule look like if I participate?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the First-line Treatment With Dacomitinib Plus Anlotinib for Patients With Advanced NSCLC With EGFR 21L858R Mutations clinical trial (NCT05271916). Contact the study team or your healthcare provider for specific answers.

Question 5

How will my progress be monitored during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the First-line Treatment With Dacomitinib Plus Anlotinib for Patients With Advanced NSCLC With EGFR 21L858R Mutations clinical trial (NCT05271916). Contact the study team or your healthcare provider for specific answers.

Question 6

What support is available for managing any side effects I may experience?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the First-line Treatment With Dacomitinib Plus Anlotinib for Patients With Advanced NSCLC With EGFR 21L858R Mutations clinical trial (NCT05271916). Contact the study team or your healthcare provider for specific answers.

What this study is about